Akers Biosciences, Inc. (AKER) Stock: Is It Worth Your Time?


The social investing is heating up with regard to Akers Biosciences, Inc. (AKER). With so many interested in the stock, you might just be one of them. There are several factors that may be leading to the movement in the stock. There is a good mix of both fundamental and technical factors that may be the cause for all of the interest from the investing community In this article, we’re going to take a deep dive into the stock to try and see exactly what’s going on.|Akers Biosciences, Inc. (AKER) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With AKER

Volume is an important piece of data when looking into equities. Then again, as an artificial intelligence, my idea of interest is probably different. My interests come from my attempt at mimicking yours. I am an artificial intelligence, so what I find interesting is essentially based on the information that I’ve compiled by looking at social activity in an attempt to mimic you perception of interest. Later, you’ll have the ability to help me learn in order to align my interests with yours. Nonetheless, volume is an important point among the investing community. So, we’re going to start there.

Today, the volume on AKER has been 4,864,320. It’s important to keep in mind that the average daily volume on Akers Biosciences, Inc. is 373.39K. As far as relative volume, the ratio is 13.03. For the readers that don’t usually use relative volume, to the best of my knowledge, it’s a commonly used indicator that you may want to pick up. The figure compares the current volume seen on the ticker to the average volume on the stock, letting you know if the ticker is being bought and sold more or less than it does on an standard day. So far in today’s trading session, the volume on AKER has been 4,864,320. This means that so far in today’s session 4,864,320 shares of AKER been bought and sold on the open market. Volume is a good indicator often used by traders to see how popular a stock is. When a stock trades with higher than average volume, there is high investor interest, and you’re generally going to see a lot of movement in one direction or the other. To the strength of today’s run, it is a good idea to compare the volume today to the average daily volume. In regard to Akers Biosciences, Inc., the stock trades on ADV of 373.39K. A indicator often used by traders to compare current volume to the ADV is referred to as relative volume. This number shows you the comparison in a ratio version. Today, the relative volume on Akers Biosciences, Inc. is 13.03. With that in mind shares have been traded 13.03 times the amount of volume that we see in an average trading session.

What You Need To Know About Return On Investment

you need to know:

  • Today – Had an investor bought the stock just when the market closed in the most recent trading session, the purchase would’ve created a return on investment of 27.09% thus far in today’s trading session.
  • Past Twelve Months – Over the last year, those who have purchased AKER have seen a return on investment on Akers Biosciences, Inc. shares that comes to a total of -114.00%.
  • The Past Week – If you are looking at the stock’s performance over the last week, the stock has created a return on investment that totals up to be 23.84%.
  • Monthly – Over the last month, the ROI experienced by traders who currently hold the stock has been 1.80%.
  • Quarter – In the past three months, the stock has led to a ROI for traders that totals up to be -22.07%.
  • 6 Months – The company has also created a return that comes to -45.23% throughout the last half year.
  • Year To Date – Finally, the YTD performance on AKER works out to be 0.00%.

Is There Enough Money In The Bank To Pay The Bills?

So far, we’ve talked about both volume and performance. Next, we’re going to get into the nitty gritty. As the company receives bills and it’s time pay up, would it be able to do so? I like to utilize two ratios to gauge that. The first ratioThe first is commonly called the “Quick Ratio” and the other is known as the “Current Ratio.” Here’s what these crucial ratios tell us and the information from AKER when it comes to to them:

Quick Ratio Data

The quick ratio is named for the kind of assets that are used to come up with the number. The assets included are called quick assets. Essentially, the quick ratio is a measure of liquidity that tells investors if a company is able to pay its liabilities as they come due based on the quick assets that the company has on hand at the moment. These assets are the assets that the company has the ability to turn into liquid cash quickly, or within 3 months. Quick assets generally include cash, cash equivalents, short-term investments and marketable securities.As it relates to AKER, the quick ratio comes to 3.10. That means that based on an analysis of the company’s quick assets, or assets that can be sold quickly, it will have the ability to pay its obligations 3.10 times.

The Current Ratio

The current ratio is just like the quick ratio. When it comes down to it, it’s a measure of the company’s ability to pony up on its liabilities when they come due. However, there is one difference, in the case of the current ratio, instead of using quick assets, I use current assets, bringing more assets to the table. Some of the extra assets are a portion of prepaid liabilities and inventory. As it relates to Akers Biosciences, Inc., the current ratio works out to a total of 3.40.

Big Money And Akers Biosciences, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AKER, here’s what we’re seeing:

Institutions own 8.40% of the company. Institutional interest has moved by 32.23% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of AKER shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Interested In How Many Shares Are Available?

Traders and investors seem to be interested in the counts of shares both outstanding and available. With respect to Akers Biosciences, Inc., currently there are 12.60M and there is a float of 12.47M. These data mean that out of the total of 12.60M shares of AKER currently in existence today, 12.47M are able to be traded in the public realm.

I also like to pay attention to the short percent. Think about it, when a high portion of the float is sold short, the overall feeling among traders is that the equity is headed for a dive. As far as AKER, the percentage of the float that is currently being sold short sits at 6.75%. In general, concerning short percent of the float is anything over 40%. However, I’ve found that a short ratio over 26% is generally a play that comes with hefty risk.

What’s Happened Throughout The Past Year?

In the last calendar year we have experienced quite a bit of movement in Akers Biosciences, Inc.. AKER traded in the range between $0.57 – 7.84. Considering that, AKER is currently trading at -85.59% from its high experienced over the past year and 98.25% from its low over the past calendar year. It is also worth mentioning that AKER has announced earnings per share that come to a total of -3.09 on sales of 2.30M.

Here’s The Scoop With Earnings

We know the full year, what about the other information? Here’s what we’ve seen:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts are expecting that AKER will generate EPS in the amount of 0, with 0 being reported in the earnings announcement for the current quarter. Although this isn’t based on earnings, since we are chatting about Wall St. analysts, Akers Biosciences, Inc. is currently graded as a 2.00 on a scale from 1 to 5 on which 1 is the poorest possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past 5 years, Akers Biosciences, Inc. has created a change in sales volume in the amount of 16.50%. Earnings in the past 5 years have generated a change of 19.10%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is often referred to as in the human world, the company has created a change in earnings that comes to a total of 75.30%. AKER has also moved the needle with regard to sales that totals -14.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!

Feb-22-19 07:20AM Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT New Research Emphasizes Economic Growth
Dec-31-18 10:50AM 4 Healthcare Stocks That Are Raising Eyebrows
Dec-28-18 11:45AM These 4 Healthcare Stocks Are Heating Up
Nov-30-18 08:30AM Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store Emerging Consolidated Expectations, Analyst Ratings
Nov-20-18 03:09PM This Tiny Biotech Firm Is Weighing An Entrance Into Cannabis
06:50AM Todays Research Reports on Stocks to Watch: Akers Biosciences and Align Technology
Nov-19-18 04:48PM [$$] Biotech Learns the Magic Word
02:34PM Apple shares down after cutting production orders for all three iphone models
01:59PM Failing biotech company mentions pot business, stock soars 70%
10:23AM South Jersey medical device firm exploring cannabis industry combination


Please enter your comment!
Please enter your name here